The Diagnostic Value of 18F-FDG PET and MRI in Paediatric Histiocytosis

Overview

Journal Eur J Nucl Med Mol Imaging

Specialties Biophysics
Nuclear Medicine
Radiology

Date 2012 Oct 26

PMID 23096080

Citations 19

Authors

Wolfgang Peter Mueller

Henriette Ingrid Melzer

Irene Schmid

Eva Coppenrath

Peter Bartenstein

Thomas Pfluger

Affiliations

Soon will be listed here.

Abstract

Purpose: To analyse the diagnostic value of (18)F-FDG PET and MRI for the evaluation of active lesions in paediatric Langerhans cell histiocytosis.

Methods: We compared 21 (18)F-FDG PET scans with 21 MRI scans (mean time interval 17 days) in 15 patients (11 male, 4 female, age range 4 months to 19 years) with biopsy-proven histiocytosis. Primary criteria for the lesion-based analysis were signs of vital histiocyte infiltrates (bone marrow oedema and contrast enhancement for MRI; SUV greater than the mean SUV of the right liver lobe for PET). PET and MR images were analysed separately and side-by-side. The results were validated by biopsy or follow-up scans after more than 6 months.

Results: Of 53 lesions evaluated, 13 were confirmed by histology and 40 on follow-up investigations. The sensitivity and specificity of PET were 67 % and 76 % and of MRI were 81 % and 47 %, respectively. MRI showed seven false-positive bone lesions after successful chemotherapy. PET showed five false-negative small bone lesions, one false-negative lesion of the skull and three false-negative findings for intracerebral involvement. PET showed one false-positive lesion in the lymphoid tissue of the head and neck region and two false-positive bone lesions after treatment. Combined PET/MR analysis decreased the number of false-negative findings on primary staging, whereas no advantage over PET alone was seen in terms of false-positive or false-negative results on follow-up.

Conclusion: Our retrospective analysis suggests a pivotal role of (18)F-FDG PET in lesion follow-up due to a lower number of false-positive findings after chemotherapy. MRI showed a higher sensitivity and is indispensable for primary staging, evaluation of brain involvement and biopsy planning. Combined MRI/PET analysis improved sensitivity by decreasing the false-negative rate during primary staging indicating a future role of simultaneous whole-body PET/MRI for primary investigation of paediatric histiocytosis.

Citing Articles

Deep learning-enabled quantification of simultaneous PET/MRI for cell transplantation monitoring.

Hayat H, Wang R, Sun A, Mallett C, Nigam S, Redman N iScience. 2023; 26(7):107083.

PMID: 37416468 PMC: 10319838. DOI: 10.1016/j.isci.2023.107083.

Current progress and future trends in imaging of musculoskeletal bone tumours.

Rajakulasingam R, Botchu R J Clin Orthop Trauma. 2021; 23:101622.

PMID: 34707971 PMC: 8522479. DOI: 10.1016/j.jcot.2021.101622.

F-FDG PET/MR Assessment of Pediatric Langerhans Cell Histiocytosis.

Niu J, Liang J, Feng Q, Wang M, Wang L, Ge X Int J Gen Med. 2021; 14:6251-6259.

PMID: 34629891 PMC: 8494996. DOI: 10.2147/IJGM.S327134.

Whole-body magnetic resonance imaging in pediatric oncology - recommendations by the Oncology Task Force of the ESPR.

Schafer J, Granata C, von Kalle T, Kyncl M, Littooij A, Di Paolo P Pediatr Radiol. 2020; 50(8):1162-1174.

PMID: 32468287 PMC: 7329776. DOI: 10.1007/s00247-020-04683-4.

Functional and anatomical imaging in pediatric oncology: which is best for which tumors.

Voss S Pediatr Radiol. 2019; 49(11):1534-1544.

PMID: 31620853 DOI: 10.1007/s00247-019-04489-z.

References

Phillips M, Allen C, Gerson P, McClain K . Comparison of FDG-PET scans to conventional radiography and bone scans in management of Langerhans cell histiocytosis. Pediatr Blood Cancer. 2008; 52(1):97-101. DOI: 10.1002/pbc.21782. View

Krajicek B, Ryu J, Hartman T, Lowe V, Vassallo R . Abnormal fluorodeoxyglucose PET in pulmonary Langerhans cell histiocytosis. Chest. 2009; 135(6):1542-1549. DOI: 10.1378/chest.08-1899. View

Szturz P, rehak Z, Koukalova R, Adam Z, Krejci M, Pour L . Measuring diffuse metabolic activity on FDG-PET/CT: new method for evaluating Langerhans cell histiocytosis activity in pulmonary parenchyma. Nucl Med Biol. 2011; 39(3):429-36. DOI: 10.1016/j.nucmedbio.2011.10.002. View

Azouz E, Saigal G, Rodriguez M, Podda A . Langerhans' cell histiocytosis: pathology, imaging and treatment of skeletal involvement. Pediatr Radiol. 2004; 35(2):103-15. DOI: 10.1007/s00247-004-1262-0. View

Drzezga A, Souvatzoglou M, Eiber M, Beer A, Furst S, Martinez-Moller A . First clinical experience with integrated whole-body PET/MR: comparison to PET/CT in patients with oncologic diagnoses. J Nucl Med. 2012; 53(6):845-55. DOI: 10.2967/jnumed.111.098608. View

Bombardieri E, Aktolun C, Baum R, Bishof-Delaloye A, Buscombe J, Chatal J . FDG-PET: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 2004; 30(12):BP115-24. DOI: 10.1007/s00259-003-1355-2. View

Pavlik M, Bloom D, Ozgonenel B, Sarnaik S . Defining the role of magnetic resonance imaging in unifocal bone lesions of langerhans cell histiocytosis. J Pediatr Hematol Oncol. 2005; 27(8):432-5. DOI: 10.1097/01.mph.0000175407.19557.b8. View

Goo H, Yang D, Ra Y, Song J, Im H, Seo J . Whole-body MRI of Langerhans cell histiocytosis: comparison with radiography and bone scintigraphy. Pediatr Radiol. 2006; 36(10):1019-31. DOI: 10.1007/s00247-006-0246-7. View

Mentzel H, Kentouche K, Sauner D, Fleischmann C, Vogt S, Gottschild D . Comparison of whole-body STIR-MRI and 99mTc-methylene-diphosphonate scintigraphy in children with suspected multifocal bone lesions. Eur Radiol. 2004; 14(12):2297-302. DOI: 10.1007/s00330-004-2390-5. View

10.

Grois N, Fahrner B, Arceci R, Henter J, McClain K, Lassmann H . Central nervous system disease in Langerhans cell histiocytosis. J Pediatr. 2010; 156(6):873-881.e1. DOI: 10.1016/j.jpeds.2010.03.001. View

11.

Grois N, Tsunematsu Y, Barkovich A, Favara B . Central nervous system disease in Langerhans cell histiocytosis. Br J Cancer Suppl. 1994; 23:S24-8. PMC: 2149701. View

12.

Gadner H, Grois N, Potschger U, Minkov M, Arico M, Braier J . Improved outcome in multisystem Langerhans cell histiocytosis is associated with therapy intensification. Blood. 2007; 111(5):2556-62. DOI: 10.1182/blood-2007-08-106211. View

13.

Grois N, Potschger U, Prosch H, Minkov M, Arico M, Braier J . Risk factors for diabetes insipidus in langerhans cell histiocytosis. Pediatr Blood Cancer. 2005; 46(2):228-33. DOI: 10.1002/pbc.20425. View

14.

Gadner H, Grois N, Arico M, Broadbent V, Ceci A, Jakobson A . A randomized trial of treatment for multisystem Langerhans' cell histiocytosis. J Pediatr. 2001; 138(5):728-34. DOI: 10.1067/mpd.2001.111331. View

15.

Blum R, Seymour J, Hicks R . Role of 18FDG-positron emission tomography scanning in the management of histiocytosis. Leuk Lymphoma. 2003; 43(11):2155-7. DOI: 10.1080/1042819021000032908. View

16.

Buchler T, cervinek L, Belohlavek O, Kantorova I, Mechl M, Nebesky T . Langerhans cell histiocytosis with central nervous system involvement: follow-up by FDG-PET during treatment with cladribine. Pediatr Blood Cancer. 2004; 44(3):286-8. DOI: 10.1002/pbc.20175. View

17.

Kellenberger C, Epelman M, Miller S, Babyn P . Fast STIR whole-body MR imaging in children. Radiographics. 2004; 24(5):1317-30. DOI: 10.1148/rg.245045048. View

18.

Schmidt S, Eich G, Geoffray A, Hanquinet S, Waibel P, Wolf R . Extraosseous langerhans cell histiocytosis in children. Radiographics. 2008; 28(3):707-26. DOI: 10.1148/rg.283075108. View

19.

Hoover K, Rosenthal D, Mankin H . Langerhans cell histiocytosis. Skeletal Radiol. 2006; 36(2):95-104. DOI: 10.1007/s00256-006-0193-2. View

20.

Binkovitz L, Olshefski R, Adler B . Coincidence FDG-PET in the evaluation of Langerhans' cell histiocytosis: preliminary findings. Pediatr Radiol. 2003; 33(9):598-602. DOI: 10.1007/s00247-003-0943-4. View